Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Ramaco To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ramaco between July 31, 2025 and October 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, ...

Core Insights - The Pennant Group, Inc. reported strong financial results for the year 2025, with significant increases in revenue, net income, and adjusted earnings per share, indicating robust growth in its home health, hospice, and senior living services [1][2][4]. Financial Performance - Total revenue for 2025 was $947.7 million, a 36.3% increase from the previous year, with fourth-quarter revenue reaching $289.3 million, up 53.2% year-over-year [2][22]. - Net income for the full year was $29.6 million, a 31.1% increase, while fourth-quarter net income was $8.6 million, up 50.0% compared to the prior year quarter [2][3]. - Adjusted net income for 2025 was $41.6 million, reflecting a 38.9% increase, with fourth-quarter adjusted net income at $12.2 million, up 43.1% year-over-year [2][32]. Segment Performance - Home Health and Hospice Services segment revenue for 2025 was $732.7 million, a 41.0% increase, with fourth-quarter revenue at $233.3 million, up 64.3% [2][22]. - Senior Living Services segment revenue for 2025 was $215.0 million, a 22.3% increase, with fourth-quarter revenue at $56.1 million, up 19.6% [2][27]. Operational Metrics - Total home health admissions for 2025 were 86,076, a 44.1% increase, with fourth-quarter admissions at 28,941, up 81.3% [2][24]. - Hospice average daily census for 2025 was 4,204, a 28.6% increase, with fourth-quarter census at 5,060, up 46.9% [2][27]. - Senior living average occupancy for the fourth quarter was 80.6%, an increase of 200 basis points year-over-year, with average monthly revenue per occupied room at $5,238, up 5.6% [2][27]. Guidance for 2026 - The company anticipates total revenue for 2026 to be between $1,133.6 million and $1,171.8 million, with adjusted earnings per diluted share expected to be between $1.26 and $1.36 [5][6]. - Adjusted EBITDA for 2026 is projected to be between $88.5 million and $94.1 million [5][6]. Management Commentary - The CEO highlighted 2025 as a year of record-breaking performance and strategic growth, emphasizing the importance of operational excellence and successful integration of new operations [4][6]. - The COO noted the focus on maintaining momentum and delivering strong results across all key growth metrics, indicating confidence in continued success in 2026 [4][6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kyndryl To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Kyndryl between August 7, 2024 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Faruqi ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Smart Digital To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Smart Digital between May 5, 2025 and September 26, 2025 at 9:34 AM EST and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading na ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Endeavor To Contact Him Directly To Discuss Their Options If you sold Endeavor Class A common stock between January 15, 2025 and March 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bath & Body Works To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Bath & Body Works between June 4, 2024 and November 19, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 25, 2026 (GLOBE N ...

Core Insights - Crescent Capital BDC, Inc. reported a net investment income of $1.81 per share and a net income of $0.93 per share for the year ended December 31, 2025, with a quarterly net investment income of $0.45 and net income of $0.23 for the quarter ended December 31, 2025 [1][7][9] - The company declared a regular cash dividend of $0.42 per share for the first quarter of 2026, payable on April 15, 2026 [1] Financial Highlights - As of December 31, 2025, total investments at fair value were $1,569.4 million, a decrease from $1,598.9 million as of December 31, 2024 [2][3] - Total assets were reported at $1,622.1 million, down from $1,656.3 million a year earlier [2] - Net asset value (NAV) per share was $19.10, compared to $19.98 as of December 31, 2024 [2][17] - Investment income for the year decreased to $167.3 million from $197.4 million in 2024, primarily due to lower interest income [7][8] - Total expenses for the year were $100.4 million, down from $108.4 million in 2024 [8] Portfolio & Investment Activity - The company invested $306.9 million across 25 new portfolio companies and 41 existing portfolio companies during the year ended December 31, 2025 [5] - For the fourth quarter of 2025, investments totaled $70.8 million across five new portfolio companies [6] - The portfolio consisted of 184 companies as of December 31, 2025, with a significant portion in unitranche first lien investments, accounting for 66.7% of the total fair value [3][4] Liquidity and Capital Resources - As of December 31, 2025, the company had $31.5 million in cash and cash equivalents, along with $242.0 million of undrawn capacity on its credit facilities [11] - The weighted average cost of debt was reported at 5.83%, with a debt to equity ratio of 1.25x [11]

Core Viewpoint - Purple Biotech Ltd. is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares to regain compliance with Nasdaq's minimum bid price requirement, effective March 2, 2026 [1][2]. Group 1: ADS Ratio Change - The ADS Ratio will change from 1 ADS representing 200 ordinary shares to 1 ADS representing 2,000 ordinary shares, effectively a one-for-ten reverse ADS split [1][2]. - Registered holders of certificated ADSs must surrender their ADSs for cancellation to receive new ADSs, while holders of uncertificated ADSs will have their ADSs automatically exchanged [2]. - The new CUSIP number assigned due to the ADS Ratio Change is 74638P307, and the ADSs will continue to trade under the symbol "PPBT" on Nasdaq [2]. Group 2: Impact on Trading - The ADS trading price is expected to increase proportionally as a result of the ADS Ratio Change, enhancing its suitability for trading on Nasdaq [4]. - There is no assurance that the ADS trading price post-change will be equal to or greater than ten times the price before the change [4]. Group 3: Company Overview - Purple Biotech is a clinical-stage oncology company focused on developing therapies to overcome tumor immune evasion and drug resistance [5]. - The lead program, CAPTN-3, involves capped tri-specific antibodies targeting tumors while engaging T cells and NK cells, with candidates IM1240 and IM1305 in various stages of development [5]. - The pipeline includes clinical-stage assets like CM24 and NT219, targeting specific cancer types with promising outcomes in clinical studies [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Enphase To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Enphase between April 22, 2025 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Faruqi ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Mereo between June 5, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Fa ...